Biomarkers with known biological significance in CRC, including TP53 mutations, MSI status and CIN markers such as FGA, aneuploidy score, in addition to the direct PARPi targets—PARP1 and PARP2—were interrogated for their potential utility as PARPi response biomarkers. The gene discussed is TP53; the disease is colorectal carcinoma.